PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Meropenem→

Meropenem PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
96036-03-2
Molecular formula
C17H25N3O5S
Molecular weight
383.5 g/mol
Drug class
Carbapenem beta-lactam antibacterialbroad-spectrum parenteral antibiotic
Mechanism of action
Binds penicillin-binding proteins and inhibits bacterial cell-wall peptidoglycan synthesis, causing bactericidal activity against susceptible Gram-positive, Gram-negative and anaerobic organisms.
Indications / reported uses
  • Treatment of serious bacterial infections caused by susceptible organisms, including complicated intra-abdominal infections, complicated skin/soft-tissue infections, meningitis and selected hospital-acquired infections; indication and dose depend on age, site, renal function and local susceptibility

Sources: US DailyMed — Meropenem injection · NLM MeSH — Meropenem · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Meropenem PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Meropenem Permitted Daily Exposure (PDE) report (the Meropenem PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Meropenem Occupational Exposure Limit (OEL) report (the Meropenem OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.